Samsung Biologics has signed a letter of intent for a contract manufacturing organization (CMO) agreement worth 150 billion KRW with a US pharmaceutical company.
Samsung Biologics announced on the 5th that it had signed a letter of intent for a biopharmaceutical contract manufacturing agreement worth 147.2845 billion KRW with a US-based pharmaceutical company. The contracting party was not disclosed due to business confidentiality.
The contract amount corresponds to 4.91% of Samsung Biologics' sales revenue last year. The contract period is from the date of signing the letter of intent until the signing of the final contract.
Samsung Biologics stated, "The contract amount is binding between the two parties," and added, "If the final contract is signed in the future, the confirmed details will be disclosed."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
